Table 2:

Associations with adverse outcomes

Predictor	Death		Death/Intubation/High Flow nasal cannula
	OR (95%CI)	P-value	OR (95%CI)	P-value
Gender: Male vs. female	2.3 (0.55,9.61)	0.33	1.44 (0.48,4.32)	0.59
BMI: > 30 vs < 30	2.0 (0.5,8)	0.44	1.66 (0.5,5.49)	0.53
History of current/former smoking: Yes vs. No	2.6 (0.7,9.8)	0.18	3.9 (1.27,11.98)	0.022
Age: >60 vs. < 60 years	4.5 (0.89,22.79)	0.09	4.46 (1.28,15.52)	0.027
≥ 3 comorbidities: Yes vs. No	6.55 (1.29,33.26)	0.019	3.37 (1.08,10.48)	0.055
Disease: AML vs. all others	4.7 (1.2,18.3)	0.028	2.99 (0.93,9.6)	0.072
Treatment prior to COVID-19:   – Last treatment < 3 months vs. > 3 months   – Prior allo-SCT vs. no prior allo-SCT	5.22 (1.03,26.45) 2.0 (0.5,8)	0.047 0.44	1.37 (0.47,4.04) 2.4 (0.73,7.83)	0.60 0.21
Laboratory values:   – Neutropenia: ANC < 1000/uL vs. > 1000/uL   – Lymphocytopenia: ALC < 500/uL vs. > 500/uL   – Albumin: Alb < 3.5 vs. > 3.5   – Creatinine 1.3: Yes vs. No   – ALT > 55: Yes vs. No   – AST > 37: Yes vs. No   – Total bilirubin > 1.2: Yes vs. No	11.75 (2.72,50.74) 0.55 (0.14,2.22) 9.0 (1.92,42.14) 0.72 (0.13,3.94) 4.43 (0.88,22.17) 9.0 (1.92,42.14) 4.0 (0.68,23.67)	0.001* 0.48 0.004 1.0 0.079 0.004 0.13	4.85 (1.39,16.94) 0.24 (0.1–1.1) 8.8 (2.2,35.15)) 1.1 (0.27,4.45) 3.61 (0.74,17.64) 5.48 (1.46,20.48) 1.86 (0.33,10.45)	0.018 0.081 0.003* 1.0 0.13 0.012 0.66

^*remains statistically significant after Bonferroni correction (p < 0.0033)